Regeneron announces FDA acceptance of sBLA filing for 12-week dosing of EYLEA(R)
Regenero announced the FDA has accepted for review the Company's sBLA for a 12-week dosing interval of EYLEAź (aflibercept) Injection in patients with wet age-related macular degeneration based on physician's assessment. The PDUFA target action date is August 11, 2018. December 11, 2017